Levosert (Levonorgestrel)

Levonorgestrel released from Levosert acts locally in the uterus to thicken cervical mucus, impair sperm motility, suppress the growth of the endometrium, and occasionally inhibit ovulation. These combined actions create an environment that prevents fertilisation and implantation.

Levosert is supplied as a single intrauterine device that releases approximately 20 µg of levonorgestrel per day for up to five years. The exact dosing regimen, including timing of insertion and removal, is determined by the prescribing healthcare professional.

Levosert is contraindicated in pregnancy (Category X) and must not be inserted in a pregnant woman. For breastfeeding women, insertion after delivery is generally considered safe, but patients should discuss any concerns with their healthcare provider.

To order Levosert, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Levosert releases levonorgestrel, offering hormonal contraception, reduced menstrual bleeding and potential improvement of dysmenorrhoea, whereas copper IUDs provide non‑hormonal contraception and may increase menstrual flow. Both are highly effective, but the choice depends on a woman's preference for hormonal versus non‑hormonal methods and her bleeding profile.

Levosert should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and physical damage until it is inserted by a qualified healthcare professional.

Levosert is inserted into the uterine cavity by a trained clinician using a specialized inserter. The procedure is performed in a clinical setting after confirming the patient is not pregnant and that the uterus is suitable for device placement.

Serious risks include uterine perforation during insertion, expulsion of the device, pelvic inflammatory disease, ectopic pregnancy if contraception fails, allergic reactions to device components, and migration of the IUS to adjacent organs. Prompt medical evaluation is required if any of these events are suspected.

Levosert should not be used by women who are pregnant, have known or suspected uterine anomalies (e.g., large fibroids, septate uterus), have active pelvic infection, have a history of breast cancer that is estrogen‑dependent, or have severe liver disease. Contraindications are confirmed by the prescribing clinician.